What We Know and Don’t Know About l -Arginine and NO
2000; Lippincott Williams & Wilkins; Volume: 101; Issue: 18 Linguagem: Inglês
10.1161/01.cir.101.18.2126
ISSN1524-4539
Autores Tópico(s)Heart Rate Variability and Autonomic Control
ResumoHomeCirculationVol. 101, No. 18What We Know and Don't Know About l-Arginine and NO Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessEditorialPDF/EPUBWhat We Know and Don't Know About l-Arginine and NO Joseph Loscalzo Joseph LoscalzoJoseph Loscalzo From Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Mass. Originally published9 May 2000https://doi.org/10.1161/01.CIR.101.18.2126Circulation. 2000;101:2126–2129In the latter half of the nineteenth century, amyl nitrate, sodium nitrite, and nitroglycerin were each shown to relieve angina pectoris. These early observations, coupled with the rapid growth of the chemical and pharmaceutical industries, led to the development of nitrovasodilator drugs as the cornerstone of therapy for ischemic heart disease throughout most of the next century. Despite a rather thorough understanding of the pharmacology of these agents, only recently have the vascular actions of nitrovasodilators been placed in their proper biological context. The identification of nitric oxide (NO) as a product of the normal endothelium with smooth-muscle relaxing effects123 led to the recognition that nitrovasodilators work by providing an exogenous source of NO to the diseased blood vessel. As such, nitrovasodilators may be viewed as replacement therapy for the ailing vasculature.Over the past 10 years, this paradigm has been strengthened by the observation that the normal endothelium can become dysfunctional when exposed to risk factors for atherothrombosis.4 In addition, in the setting of many vascular disorders, including essential hypertension and atherothrombosis itself, endothelial dysfunction is apparent. Dysfunctional endothelium is defined by a change in its essential phenotype5 : the normal endothelial cell promotes vascular smooth muscle cell relaxation, inhibits platelet activation, limits leukocyte adhesion, and inhibits vascular smooth muscle proliferation; the dysfunctional endothelial cell, in the extreme, cannot support smooth muscle relaxation, cannot inhibit platelet activation, is avid for leukocytes, and cannot inhibit vascular smooth muscle cell proliferation. There are varying degrees of endothelial dysfunction, and these may be quantified by different functional assays, including endothelium-dependent vasodilator responses and adhesion molecule expression.Central to the development of endothelial dysfunction, regardless of its cause, is a loss of bioactive endothelial NO. NO is an important endothelial mediator for each of the principal properties of a normal endothelial cell, and a loss of bioactive NO is associated with endothelial cell dysfunction. The two fundamental mechanisms for the loss of NO bioactivity are reduced synthesis and increased oxidative inactivation by reactive oxygen intermediates. Reactive oxygen species are produced in abundance in those very vascular disorders that are accompanied by endothelial dysfunction. Limiting the generation of reactive oxygen species, especially superoxide, hydrogen peroxide, lipid peroxides, hydroxyl radical, and lipid peroxyl radicals, limits the oxidative inactivation of NO to nitrite, nitrate, peroxynitrite, and lipid peroxynitrites. For this reason, antioxidant therapy has been used in atherothrombosis and hypercholesterolemia to improve endothelial function.6 Cholesterol-lowering therapy with HMG-CoA reductase inhibitors improves endothelial function, in part by reducing the availability of reactive oxygen species.7An alternative approach to increasing bioactive NO and improving endothelial function is to increase the synthesis of the endogenous nitrovasodilator. Increased synthesis of NO can be achieved by increasing the availability of agonists that stimulate release of NO for the endothelial cell or by providing additional enzyme substrate or cofactors. ACE inhibitors, for example, improve endothelial function by decreasing degradation of bradykinin, an endogenous agonist for NO release from the endothelium.8Another straightforward approach to increasing NO synthesis is to provide additional substrate to the endothelial cell. NO is synthesized in the endothelium by the endothelium-specific isoform of NO synthase, eNOS. The semiessential amino acid l-arginine serves as the principal substrate for the enzyme. First identified in extracts of etiolated lupine seedlings by Schultz and Steiger in 1886,9l-arginine was shown to be a product of protein hydrolysis by Hedin10 nine years later; its structure was not proven until 1910 by Sorenson.11 While much is known about the intermediary metabolism of l-arginine and its role in nitrogen balance and homeostasis, the importance of this amino acid was heightened by the recent recognition that it serves as the precursor for NO synthesis: NO synthases catalyze the 5-electron oxidation of l-arginine to l-citrulline and produce stoichiometric amounts of NO in the process. Providing supplemental substrate to individuals with inadequate NO, therefore, has been suggested as a rational approach to increasing NO production by the endothelium, and this therapeutic paradigm has met with some success in recent years.In 1992, Creager and colleagues12 demonstrated that supplemental l-arginine improves endothelial NO-mediated forearm vasodilator responses in hypercholesterolemic subjects. In the same year, intravenous l-arginine was shown to improve endothelial vasodilator function in atheromatous left anterior descending coronary arteries.13 Since that time, numerous studies have confirmed that both the acute administration of l-arginine and its chronic oral administration improve vascular function in hypercholesterolemia,14 in small-vessel disease,15 in exercising patients with stable angina pectoris,16 and at sites of coronary artery stenosis.17l-Arginine is believed to evoke these benefits not only by providing eNOS with substrate to enhance NO synthesis, but also by an indirect antioxidant effect, especially in hypercholesterolemia, where its use is accompanied by decreased release of superoxide anion from the endothelium.18Although these effects are consistent and convincing, the precise molecular mechanisms by which l-arginine improves endothelial function remain puzzling. The availability of l-arginine for reaction with eNOS does not appear to be rate limiting: the intracellular levels of the amino acid are in the millimolar range,19 whereas the enzyme's Km for substrate is in the micromolar range.20 For this reason, other possible explanations have been proposed to explain the effects of l-arginine, and these will be reviewed next.Investigators have considered several direct mechanisms for the beneficial effects of l-arginine on NO production. Arginase activity is increased in plasma of individuals with vascular disease, and one group has argued that supplemental l-arginine can be used to overcome arginase activity and increase steady-state levels of the amino acid in plasma.21l-Arginine is first converted to NG-hydroxy-l-arginine by eNOS,22 and alternative pathways for N-hydroxylation of l-arginine may increase the availability of this reaction intermediate, which could facilitate substrate turnover by the enzyme. In addition, NG-hydroxy-l-arginine inhibits arginase and may thereby increase intracellular steady-state levels of l-arginine.21 Clearly, supplemental l-arginine does increase plasma levels of the amino acid, but owing to the great difference between substrate concentration and Km, substrate availability is unlikely to be rate limiting even in the presence of arginase. Another interesting possible mechanism relevant to individuals with atherothrombotic disease is that oxidized LDL and lysophosphatidylcholine decrease l-arginine transport into endothelial cells.2324l-Arginine competes with other cationic amino acids for transport into cells, especially l-glutamine, and increased l-arginine may increase intracellular substrate concentration by competitively enhancing cellular uptake in this setting. A recent report by Miyazaki et al25 suggests that atherothrombotic individuals have increased levels of a derivative of l-arginine, asymmetric dimethylarginine (ADMA), a naturally occurring competitive inhibitor of NO synthases. Although ADMA indeed appears to inhibit l-arginine turnover by eNOS, without knowledge of the specific Ki for eNOS, the functional importance of this amino acid derivative in vivo remains an open question.Proposed indirect mechanisms by which l-arginine increases bioactive NO in the vasculature are equally diverse. l-Arginine increases insulin secretion,26 which itself promotes vasodilation. In addition, l-arginine stimulates histamine release from mast cells,27 which also evokes a vasodilator response. Administered as the hydrochloric acid salt, l-arginine induces an extracellular acidosis that in turn can transiently alter intracellular pH and thereby affect pH-dependent cell-signaling pathways, including calcium transients, that modulate eNOS activity and NO synthesis. Acidic microenvironments can also support the nonenzymatic reduction of nitrite to NO,28 suggesting yet another mechanism for the benefits of l-arginine hydrochloride. Lastly, l-arginine can attenuate norepinephrine activity, thereby indirectly enhancing the effects of endogenous vasodilators, including NO.29In this issue of Circulation, Blum et al30 attempt to build on this growing body of evidence for the beneficial effects of supplemental l-arginine by administering oral l-arginine chronically to individuals with established coronary artery disease. In this randomized, double-blind crossover study, the investigators assessed flow-mediated brachial artery dilation and cell adhesion molecule expression before and after one month of therapy. In contrast to prior studies, they failed to find an effect of supplemental l-arginine on these measures of NO bioactivity.These results, although discordant with prior published data, are not entirely surprising given the speculative basis for the reported benefits of l-arginine in other study groups. There are, in addition, several possible explanations for this outcome that are unique to this study. First and most important, there was no evidence that this dose of supplemental l-arginine actually increased NO production. One previous study reported increases in expired NO gas in individuals given supplemental l-arginine at similar doses.31 Expired NO was not measured in that study; rather, nitrogen oxides were measured in serum, and no increase was detected compared with placebo treatment. Every other negative result follows from and is consistent with this lack of an increase in measurable NO or its metabolites: if NO production is not increased by the treatment regimen, then its bioactivity as measured by flow-mediated brachial artery dilation or cell adhesion molecule expression will also not increase.Why did l-arginine not increase NO production in this study population? Since serum l-arginine levels increased, the possibilities include either limited cellular uptake, competitive inhibition of eNOS (by ADMA?), or limited cofactor availability for eNOS. In light of the arguments raised above, I remain unconvinced that transport or intracellular substrate concentrations are limiting, even in the presence of established atherothrombotic disease. Vascular disease and vascular oxidant stress lead to two additional molecular and biochemical changes in the vascular environment that can modulate NO bioactivity. First, risk factors for atherothrombotic disease are accompanied by limited availability of the critical eNOS cofactor, tetrahydrobiopterin.32 In the absence of sufficient tetrahydrobiopterin, NO synthase changes its functional profile: instead of oxidizing l-arginine, the enzyme reduces molecular oxygen to superoxide anion, even in the setting of adequate substrate concentrations. The nonspecific antioxidant effects of l-arginine would not overcome this cofactor limitation because only specific synthesis of tetrahydrobiopterin from dihydrobiopterin will suffice, and this requires folate-dependent catalysis by methylenetetrahydrofolate reductase.33 Second, in atherothrombotic disease, the inducible isoform of NO synthase (iNOS) is expressed in the atherothrombotic vasculature.34 This isozyme is much more catalytically active than eNOS and consumes more substrate and cofactors than does eNOS. Furthermore, this isozyme can also serve as a source of superoxide anion in the absence of sufficient substrate or cofactors (specifically, tetrahydrobiopterin). Superoxide flux from iNOS (induced in vascular smooth muscle cells and [microvascular] endothelial cells and present in atherosclerotic plaque34 ) can oxidatively inactivate NO by the mechanisms described above. Thus, the oxidative vascular environment of the atheromatous arteries in these study subjects limits both NO activity and NO production by a variety of potential mechanisms despite adequate l-arginine.Another possible explanation for the lack of effect of supplemental l-arginine is that the study subjects' prior drug regimens, on average, improved endothelial function to a degree beyond which further improvement could not be realized. Placebo-treated patients had more than a 6-fold increase in brachial artery flow, and this significant increase in flow was unaffected by l-arginine therapy. In addition, flow-mediated dilation was in the normal range for placebo as well as l-arginine treatment arms. Statin and ACE inhibitor therapy have been shown to improve endothelial function. In addition, β-blockers and aspirin have (weak) antioxidant activity. Thus, optimal improvement in endothelial function may have been achieved by the contemporaneous use of other agents known to improve endothelial function, thereby confounding possible effects of l-arginine itself.Should l-arginine continue to be investigated as a beneficial agent in the treatment of individuals with endothelial dysfunction? In my view, the answer to this question remains affirmative. The lack of benefit in the present study has several explanations that can and should be investigated in future trials. The absence of a clear explanation for its benefit in prior studies should serve as the basis for future studies designed to address mechanism. The deceptive simplicity of the initial rationale for the use of l-arginine therapy in vascular disease has proven difficult to reconcile with biochemical data, yet its clinical benefits are supported by many studies. More than 75 years passed before the mechanism of action of nitrovasodilators was identified and their relationship to NO recognized. The possible actions of l-arginine are at least as complex, and unraveling its mechanism(s) of action may also require the careful thought and insight that only time permits.Reprint requests to Dr Joseph Loscalzo, Department of Medicine, Boston University School of Medicine, 88 E Newton St, Boston, MA 02118-2394. The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association. References 1 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature.1980; 288:373–376.CrossrefMedlineGoogle Scholar2 Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A.1987; 84:9265–9269.CrossrefMedlineGoogle Scholar3 Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature.1987; 327:524–526.CrossrefMedlineGoogle Scholar4 Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med.1995; 332:512–521.CrossrefMedlineGoogle Scholar5 Freedman JE, Loscalzo J. Endothelial dysfunction and atherothrombotic occlusive disease. Drugs.1997; 3:41–50.Google Scholar6 Gocke N, Keaney JF Jr, Frei B, Holbrook M, Olesiak M, Zachariah BJ, Leeuwenburgh C, Heinecke JW, Vita JA. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation.1999; 99:3234–3240.CrossrefMedlineGoogle Scholar7 Yamamoto A, Hoshi K, Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol.1998; 361:143–149.CrossrefMedlineGoogle Scholar8 Mombouli JV. ACE inhibition, endothelial function and coronary artery lesions: role of kinins and nitric oxide. Drugs. 1997;54(suppl 5):12–22.Google Scholar9 Schultz E, Steiger E. Über das Arginin. Z Physiol Chem.1886; 11:43–65.Google Scholar10 Hedin SG. Über die Bildung von Arginin aus Proteinkörper. Z Physiol Chem.1895; 21:155–168.Google Scholar11 Sorensen SPL. Über die Synthese des dl-Arginins (α-amino-δ-guanidino-n-Valeriansaure) und der Isomeren δ-guanidino-α-amino-n-Valeriansaure). Chem Ber.1910; 43:643–651.CrossrefGoogle Scholar12 Creager MA, Gallagher SM, Girerd XJ, Dzau VJ, Cooke JP. l-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest.1992; 90:1248–1253.CrossrefMedlineGoogle Scholar13 Dubois-Rande JL, Zelinsky R, Roudot F, Chabrier PE, Castaigne A, Geschwind H, Adnot S. Effects of infusion of l-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. Am J Cardiol.1992; 70:1269–1275.CrossrefMedlineGoogle Scholar14 Clarkson P, Adams RM, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral l-arginine improves endothelium-dependent dilation of hypercholesterolemic young adults. J Clin Invest.1996; 97:1989–1994.CrossrefMedlineGoogle Scholar15 Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by l-arginine. Lancet.1991; 67:1301–1308.Google Scholar16 Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral l-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol.1997; 80:331–333.CrossrefMedlineGoogle Scholar17 Tousoulis D, Davies GJ, Tentolouris C, Crake T, Toutouzas P. Coronary stenosis dilation induced by l-arginine. Lancet.1997; 349:1812–1813.CrossrefMedlineGoogle Scholar18 Boger RH, Bode-Boger SM, Mugge A, Kienke S, Brandes R, Dwenger A, Frolich JC. Supplementation of hypercholesterolaemic rabbits with l-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis.1995; 117:273–284.CrossrefMedlineGoogle Scholar19 Gold ME, Bush BA, Ignarro LJ. Depletion of arterial l-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun.1989; 164:714–721.CrossrefMedlineGoogle Scholar20 Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A.1990; 87:682–685.CrossrefMedlineGoogle Scholar21 Buga GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP, Cederbaum SK, Ignarro LJ. Arginase activity in endothelial cells: inhibition by NG-hydroxy-l-arginine during high-output NO production. Am J Physiol.1996; 271:H1988–H1998.MedlineGoogle Scholar22 Zembowicz A, Hecker M, Macarthur H, Sessa WC, Vane JR. Nitric oxide and another potent vasodilator are formed from NG-hydroxy-l-arginine by cultured endothelial cells. Proc Natl Acad Sci U S A.1991; 88:11172–11176.CrossrefMedlineGoogle Scholar23 Jay MT, Chirico S, Siow RC, Bruckdorfer KR, Jacobs M, Leake DS, Pearson JD, Mann GE. Modulation of vascular tone by low-density lipoproteins: effects on l-arginine transport and nitric oxide synthesis. Exp Physiol.1997; 82:349–360.CrossrefMedlineGoogle Scholar24 Kikuta K, Sawamura T, Miwa S, Hashimoto N, Masaki T. High-affinity arginine transport of bovine aortic endothelial cells is impaired by lysophosphatidylcholine. Circ Res.1998; 83:1088–1096.CrossrefMedlineGoogle Scholar25 Miyazaki H, Matsuoka H, Cooke JP, Usiu M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation.1999; 99:1141–1146.CrossrefMedlineGoogle Scholar26 Giuliano D, Marfella R, Verazzo G, Acampora R, Coppola L, Cozzolino D, D'Onofrio F. The vascular effects of l-arginine in humans: the role of endogenous insulin. J Clin Invest.1997; 99:433–438.CrossrefMedlineGoogle Scholar27 Giraldelo CM, Zappellini A, Muscara MN, DeLuca IM, Hyslop S, Cirino G, Zatz R, DeNucci G, Antunes E. Effect of arginine analogues on rat hind paw oedema and mast cell activation in vitro. Eur J Pharmacol.1994; 257:87–93.CrossrefMedlineGoogle Scholar28 Zweier JL, Samouilov A, Kuppusamy P. Non-enzymatic nitric oxide synthesis in biological systems. Biochim Biophys Acta.1999; 1411:250–262.CrossrefMedlineGoogle Scholar29 Chin-Dusting JPF, Alexander CT, Arnold PJ, Hodgson WC, Lus AS, Jennings GLR. Effects of in vivo and in vitro l-arginine supplementation on healthy human vessels. J Cardiovasc Pharmacol.1996; 28:158–166.CrossrefMedlineGoogle Scholar30 Blum A, Hathaway L, Mincemoyer R, Schenke WH, Kirby M, Csako G, Waclawiw MA, Panza JA, Cannon RO III. Oral l-arginine in patients with coronary artery disease on medical management. Circulation.2000; 101:2160–2164.CrossrefMedlineGoogle Scholar31 Mehta S, Stewart DJ, Levy RD. The hypotensive effect of l-arginine is associated with increased expired nitric oxide in humans. Chest.1996; 109:1550–1555.CrossrefMedlineGoogle Scholar32 Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest.1997; 99:41–46.CrossrefMedlineGoogle Scholar33 Matthews RG, Kaufman S. Characterization of the dihydropterin reductase activity of pig liver methylenetetrahydrofolate reductase. J Biol Chem.1980; 255:6014–6017.MedlineGoogle Scholar34 Buttery LD, Springall DR, Chester AH, Evans TJ, Standfield EN, Parums DV, Yacoub MH, Polak JM. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest.1996; 75:77–85.MedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByNitz K, Lacy M and Atzler D (2019) Amino Acids and Their Metabolism in Atherosclerosis, Arteriosclerosis, Thrombosis, and Vascular Biology, 39:3, (319-330), Online publication date: 1-Mar-2019. May 9, 2000Vol 101, Issue 18Article InformationMetrics Download: 656 Copyright © 2000 by American Heart Associationhttps://doi.org/10.1161/01.CIR.101.18.2126 Originally publishedMay 9, 2000 Keywordsamino acidsnitric oxideEditorialsatherosclerosisPDF download
Referência(s)